MedTech Strategist Issue: Vol. 5, No. 14 - October 17, 2018


Already a Subscriber?


Not a Subscriber?

Medtech Investing - “MD Start: Building Medtech Companies in Europe”

By David Cassak, Co-Editor-in-Chief

Although European physicians have been behind some of the most important technological and clinical advances, Europe has trailed the US in creating the medical device companies that bring those advances to market. Paris-based MD Start has created a model for building companies that, while global in scope, could help Europe overcome its sluggish track record.



Orthobiologics - “Regulatory Shifts for HCT/P Products Put Orthobiologics Manufacturers on the Spot”

Sidebar: FDA’s Evolving Criteria for Tissue-based Biologics: Takeaways
Sidebar: MiMedx Wins an Orthopedic Rarity: RMAT Designation for AmnioFix Injectable

By Wendy Diller, Senior Writer/Market Analyst

FDA’s shift in regulations is forcing companies to decide how much they want to commit to orthobiologics and in what ways. Zimmer Biomet’s decision to double down on one product in the near term, while halting work on another, indicates how it and other firms are assessing their strategies. Senior Director Joel Higgins talks about the impact of the new regulations on the company’s choices.

Outside Opinion - “Three Strategies to Avoid Medical Device Commoditization”

By Tom Dudnyk, VIVO Agency

Value-based care demands medtech companies transform the pathways, not just the products.

Interventional Radiology - “EmboMedics: Thinking Organically about Embolization”

By Colin Miller, Contributing Writer

Current embolization techniques use tiny plastic or glass microspheres that remain in the body long after their function has been accomplished, leading in many cases to ongoing inflammation. EmboMedics is introducing microspheres made of organic materials that are completely resorbable, reducing complications and increasing the efficiency of drug delivery.

Start-Ups To Watch: Cardiac Rhythm Management - “Kobara Medical: Epicardial Pacing Provides Advantages for Heart Failure Patients”

By Mary Stuart, Senior Writer/Market Analyst

Initially conceived by a physician who is an expert in heart failure, complex catheter ablations, and left atrial appendage closure, the epicardial lead from Kobara Medical enables more effective cardiac resynchronization therapy from outside the heart and blood vessels.

Kobara Medical.png

Not a Subscriber?

Already a Subscriber?

Want a Sample Article?

Companies Covered in this Issue:  Abbott Laboratories Inc., AblaCare, APD, Boston Scientific Corp., BTG PLC, CorWave SA, DePuy Synthes, EmboMedics Inc., Guerbet, Johnson & Johnson, Kobara Medical Inc., LimFlow SA, LivaNova PLC, MD Start, Medtronic PLC, Merit Medical Systems, MiMedx Group Inc., NovoNordisk AS, PreCardia, Royal Philips, SafeHeal, Shockwave Medical Inc. Smith & Nephew PLC, Stryker Corp., Zimmer Biomet Inc.

Topics Covered in this Issue: Cardiovascular/Vascular; Drug Delivery; Investment/Finance/M&As, Medtech Business Strategies/Development; Oncology; Orthopedics/Spine;  Perspective/Commentary; Regenerative Medicine/Cell Therapy; Reimbursement/Regulatory;  Start-Ups